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Abstract
Objective The aim of this study was to evaluate a multiple
immunoaffinity protein depletion (multiple affinity removal
system, MARS) pre-treatment strategy with subsequent
two-dimensional polyacrylamide gel electrophoresis (2D
PAGE) and peptide mass finger printing analysis for the
detection of ovarian cancer-associated plasma proteins.
Materials and Methods Following immunoaffinity deple-
tion, total plasma protein content was reduced by 84.2±
1.8% (mean±SE, n=32). The number of proteins detected
in the control and ovarian cancer groups was 349 and 357,
respectively. This represented an increase in spot detection
of almost twofold when compared to 2D PAGE displays of
untreated plasma (174 spots). Of the proteins displayed,
post-depletion, 300 (control) and 302 (ovarian cancer, OC)
were common within each group. PDQuest analysis
indicated that 109 protein spots were statistically different
between the two groups and, of these, 59 exhibited greater
than or equal to twofold difference in spot density
(Student’s t test, p=0.01). Thirty-nine of these proteins
were successfully identified with reliable confidence.
Results and Discussion The data obtained in this study
demonstrates that immunodepletion of plasma before 2D
PAGE profiling have generated identifiable plasma proteins
that are differentially expressed in the high-grade ovarian
cancer sample set compared to controls. This approach,
therefore, may be useful in identifying candidate bio-
markers for inclusion in multi-marker tests for ovarian
cancer that may exhibit greater sensitivity and specificity
than those currently available. It was evident, however,
from the predominant identification of host response
proteins that immunodepletion did not generate sufficient
levels of enrichment of lower abundance tumor-specific
proteins to facilitate detection.
Keywords Biomarker . Mass spectrometry .
Multiple affinity removal system (MARS) .
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Introduction
Almost 1,500 new cases of ovarian cancer were diagnosed
in Australia in 2006. The relative 5-year survival rate for
women diagnosed with ovarian cancer from 1998 to 2002
was 42%, predominantly because of diagnosis at an
advanced stage. An overall 5-year survival rate of 95%
can be achieved, however, if ovarian cancer is detected
early. The asymptomatic nature of the disease and the low
sensitivity and specificity of the currently available test
utilizing CA-125 present a major challenge for achieving
early detection [1].
Proteomic profiling has afforded insights into disease-
associated changes in protein expression and may prove its
utility in identifying ovarian cancer biomarkers [2–4].
Limitations of the proteomic profiling of human plasma
have been the interference from high-abundance proteins
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(including albumin, IgGs, and clotting cascade proteins).
Previously, solid-phase, affinity-based chromatographic
methods, such as Affigel-blue® and Affigel® Protein A,
have been used to remove such proteins from plasma [5, 6].
Recently, immunoaffinity approaches have been developed
to remove high-abundance proteins and enhance the
detection and characterization of low-abundant proteins in
human plasma [7–11]. For example, Bjorhall et al. [9] used
five different depletion columns to investigate efficiency,
specificity, and reproducibility of the techniques. They
concluded that the MARS column was the most specific
and reproducible. Martosella et al. [10] used a combination
of immunodepletion (MARS) and reversed phase high-
performance liquid chromatography (HPLC) fractionation
to produce higher quality protein identifications.
The use of MARS for plasma depletion and subsequent
identification of diagnostic biomarkers from this study is
fundamental to early detection of ovarian cancer with the
expectation of enhanced efficiency of treatment and a
subsequent increase in the rate of survival as the principal
objective.
The hypothesis to be tested in this study was that
immunodepletion of six high-abundance proteins from
plasma before two-dimensional polyacrylamide gel electro-
phoresis (2D PAGE) display would enhance the detection




The study was approved by the Royal Women’s Hospital,
Research and Human Ethics Committee, Melbourne, Aus-
tralia. Participant information statements were provided, and
informed consent was obtained before sample collection.
Blood samples were obtained by venipuncture of healthy
female volunteers (n=16), patients with benign ovarian
neoplasm (n=8), and patients with grade 3 ovarian cancer
(n=16, 12 serous and 4 clear cell carcinoma), with
collection in a 7.5-ml vacutainer (Sarstedt, Numbrecht,
Germany) containing lithium heparin as an anticoagulant.
Blood samples were centrifuged (2,000×g at 4°C), and the
separated plasma was aliquoted and stored at −80°C until
further analysis.
Depletion of High-Abundant Proteins
Affinity Column
The human multiple affinity removal system (MARS) used
in this study was a solid phase immunoaffinity column
(4.6×50 mm, Agilent Technologies, Wilmington, DE,
USA) containing monoclonal antibodies targeting albumin,
IgG, anti-trypsin, IgA, transferrin, and haptoglobin. Sample
processing was performed using an Agilent 1100 HPLC
system and proprietary reagent solutions (Agilent).
Sample Preparation
Human plasma was diluted fivefold with buffer A (a
proprietary neutral buffer, pH 7.4, containing salt) to which
a protease inhibitor cocktail (mini-complete, Roche Bio-
chemicals, Indianapolis, IN, USA) was added. The sample
was then filtered through a 0.22-μm spin tube (Agilent
Technologies, Wilmington, DE, USA) and centrifuged at
16,000×g for 1 min to remove particulates. Diluted plasma
was stored at 4°C. The sample (100 μl) was injected onto
the MARS column in 100% buffer A at a flow rate of
0.25 ml/min for 9 min. Flow-through fractions, containing
the lower abundant proteins (LAP) that did not bind to the
column, were collected in 96 well plates (Greiner Bio-One
BioScience, Frickenhausen, Germany) and stored at 4°C
within the thermostat-controlled fraction collector. The
bound fractions or high-abundant proteins (HAP) were
eluted with 100% B at a flow rate of 1.0 ml/min for
3.5 min. The column was regenerated and equilibrated with
100% buffer A for 7.5 min. The total time for each
depletion experiment was 20 min. Protein elution profiles
were monitored at a wavelength of 280 nm.
Buffer Exchange/Solvent Exchange
Depleted plasma samples were concentrated using Amicon
Ultra 5000 Dalton molecular weight cut-off centrifugal
devices according to manufacturer’s instructions (Millipore
Corporation, Billerica, MA, USA). The solvent was
exchanged by reconstituting the retentate to the original
sample load volume using 20 mM phosphate buffer,
pH 7.6. This process was repeated three times.
Protein Concentration Determination
Total protein content of each sample was determined using
the Coomassie Plus protein assay reagent kit according to
manufacturer’s instructions (Pierce Biotechnology, Rock-
ford, IL, USA) using bovine serum albumin as the standard.
Sample Pre-Conditioning for 2D PAGE Analysis
MARS depleted samples were preconditioned for 2D PAGE
analysis using a 2-D clean-up kit according to manufac-
turer’s instructions (GE Healthcare Bio-Sciences, Uppsala,
Sweden). Protein concentration was redetermined after
preconditioning.
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Two-Dimensional Gel Electrophoresis
A total of 40 μg protein was loaded onto first-dimension
Ready Strip™ gels (11 cm, pH 4–7; Bio-Rad Laboratories,
Hercules, CA, USA) after sample solubilization with
multiple chaotrope solubilization solution [200 μl, 7 M
urea; 2 M thiourea; 100 mM dithiothreitol (DTT); 4%
CHAPS; 40 mM Tris buffer; 0.5% carrier ampholytes,
pH 4–7; trace bromophenol blue] as previously described
[5, 6]. Second dimension separation was performed on
precast 10% Tris–HCl criterion gels (Bio-Rad Laboratories)
and stained with Sypro Ruby® fluorescent protein dye
(Bio-Rad Laboratories). Gels were individually scanned
using an FX imager with a 532-nm laser at 100 μm
resolution (Bio-Rad Laboratories). The protein spots were
detected, quantified, and matched using PDQuest V7.3.1
(Bio-Rad Laboratories). Each gel was normalized to the
total quantity of valid spots. The gels were then counter-
stained with colloidal coomassie brilliant blue (CBB) to
enable visualization and manual excision.
In-Gel Digestion and Peptide Analysis Using Matrix-
Assisted Laser Desorption–Ionization Time-of-Flight Mass
Spectrometry
In this study, a combination of two mass spectrometers
(Ettan MALDI-ToF Pro, GE Healthcare; MALDI Autoflex
II, Bruker Biosciences) were used to estimate peptide
masses generated from the in-gel digestion of the 2D
PAGE protein spots. The database search results and
tabulated protein identifications are from a combination of
data collected from both mass spectrometers. Only high
scoring and confident hits retrieved from the selected
databases using Mascot and ProFound™ search engines
are tabulated.
Selected protein spots were manually excised from
colloidal CBB-stained 2D gels using a spot picker (The
Gel Company, San Francisco, CA, USA, picker head, 1.5-
mm diameter). The gel plugs were rinsed by transfer into
96-well plates (Greiner Bio-One BioScience) containing
deionized water (100 μl per well, MilliQ grade). Digestion
using trypsin with subsequent application to a matrix-
assisted laser desorption–ionization time-of-flight (MALDI-
ToF) target plate (GE Healthcare and Bruker Biosciences)
was performed robotically with an Ettan Spot Handling
workstation (GE Healthcare). The gel plugs were destained
in 100 μl of 50 mM ammonium bicarbonate (Riedel-de
Haen, Germany)/50% methanol (Lab-Scan Analytical Sci-
ences, Ireland) for 30 min, then washed three times in
deionized water (100 μl, 5 mins, Milli Q grade). Gel plugs
were then incubated in 100 μl of 50 mM ammonium
bicarbonate/50% methanol for 30 min followed by incuba-
tion in 100 µl of 75% acetonitrile (ACN, Lab-Scan
Analytical Sciences, Ireland) for a further 30 min. After
drying the gel plugs (40°C, 23 min), 10 μl of sequencing
grade trypsin solution (20 ng/µl, Promega, Madison, WI,
USA) dissolved in 20 mM ammonium bicarbonate was
added and incubated (37°C for 180 min). During the
following extraction step, gel plugs were covered with
60 μl 0.1% trifluoroacetic acid (TFA, Pierce, Rockford,
USA)/50% ACN and incubated for 20 min. The peptide
containing supernatant was transferred to a new 96-well
plate, and the extraction was repeated (40 μl). The super-
natants were pooled and dried (40°C for 3 h). The peptides
were resolubilized by manually adding 50% ACN/0.1%
TFA (15 μl) into each well and gently vortexing (10 mins.,
Vortex Genie 2). The resolubilized peptide mixtures
(0.3 μl) were each combined with MALDI matrix (1.0 μl,
α-cyano-4-hydroxy cinnamic acid, 3 mg/ml in acetone/
ethanol (1:2, v/v), Bruker Biosciences) and applied (1.3 μl)
to the Anchorchip target plate using the Ettan Spot
Handling robotic workstation (GE Healthcare). Alternative-
ly, the peptide mixtures were combined with the same
MALDI matrix (1.0 μl, 3 mg/ml in 50% ACN/0.1% TFA,
Bruker Biosciences) and applied (1.3 μl) to the GE
Healthcare target plate using the Ettan Spot Handling
robotic workstation (GE Healthcare). The peptide-matrix
samples were allowed to dry on the target plates (10–
15 mins) before data collection using either of the two
described MALDI-ToF mass spectrometers.
MS Data Collection, Database Searching, and Protein
Identification
General instrument settings for the MALDI-ToF Pro MS
(GE Healthcare) are as follows: mode, reflector, and
positive ion polarity; 20 kV accelerating potential, 20 kV;
laser, 8 shots/second (200 shots per spectra); mass
range, 800–4,000 m/z. The instrument was internally cal-
ibrated using trypsin autolytic fragments (842.510 and
2211.1046 m/z).
General instrument settings for the Autoflex II MALDI-
ToF/ToF (Bruker Biosciences) are as follows: mode,
positive, and reflector; pulsed ion extraction, 120 ns; laser
intensity, 22–28%; laser frequency, 25 Hz; 600 laser shots
were collected and summed for all MS data. The mass
range (800–3,000 m/z) of the mass spectrometer was
internally calibrated using the autolytic peaks of trypsin
(842.510 and 2,211.1046 m/z). Matrix was suppressed
using a high-gating factor. Signal suppression below
800 m/z was activated. Data acquisition and processing
was performed using instrument-specific software, Ettan
MALDI-ToF Pro software 2.0 (GE Healthcare) or Flex-
Control, FlexAnalysis, and BioTools software (Bruker
Daltonics). Peaklists were generated before database
searching.
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The mass spectral data collected from the MALDI-ToF
Pro instrument was submitted to the National Centre for
Biotechnology Information nonredundant database (NCBInr,
V1.30, 22 March 2006), http://www.prowl.rockerfeller.edu/
prowl-cgi/profound.exe) using the ProFound™ search en-
gine. Data collected from the Autoflex II MALDI ToF/ToF
was submitted to the SwissProt database (release 51.0, 31
October 2006) using the Mascot search algorithm (Matrix
Science, http://www.matrixscience.com). Typical search
parameters for both search engines were as follows: mass
tolerance, 0.5 Da; missed cleavages, 2; enzyme, trypsin;
fixed modifications, carbamidomethylation; variable modifi-
cation, Oxidation (M); taxonomy, Homo sapiens.
Results
High-Abundant Protein Depletion
Total plasma protein concentration averaged 54±2.6 mg/ml
(n=32), of which 1.08±0.02 mg of protein was loaded onto
the MARS column. After depletion of HAP, protein
concentration averaged 0.17±0.02 mg/ml, representing an
average reduction in total protein content of 84.2±1.8%
(Table 1, Fig. 1).
2D PAGE
Protein profiles from 16 grade 3 (high-grade) ovarian cancer
patient plasma were analyzed, 12 with serous tumors and 4
with clear cell tumors. Sixteen healthy volunteers comprised
the control group. Analysis by 2D PAGE was performed and
a representation of each group including untreated plasma is
shown in Fig. 2. In untreated plasma (Fig. 2a), 174 proteins
spots are displayed, and the high-abundance proteins
targeted by the MARS column are clearly evident.
After depletion, 349±26 spots in the control group and
357±24 spots in the OC group were observed.
From the proteins that were displayed after depletion, 172
(normal) and 166 (OC) spots were present in all 16 members
of each group. The overall mean coefficient of variance for
all spots was 48 and 56%, respectively, as calculated by
PDQuest. A matching summary is provided for each sample
in Table 2. Between the two groups, 109 spots were
statistically different, and of these, 59 were differentially
expressed greater than or equal to twofold (Student’s t test,
p=0.01, Fig. 2b,c). Thirty-nine of these proteins have been
identified with high confidence (Tables 3 and 4).
Proteins bound to the MARS column were subsequently
eluted and also separated by 2D PAGE (Fig. 2d).
In addition to comparing grade 3 ovarian cancer with
normal MARS-depleted plasma protein displays, plasma
collected from patients with benign ovarian neoplasm were
compared with eight matched plasma samples from normal
women. This comparison allowed the identification of
proteins differentially and exclusively expressed in associ-
ation with grade 3 ovarian cancer.
A representation of the protein profile from eight benign
ovarian neoplasm patients post-HAP depletion and subse-
quent 2D PAGE is displayed in Fig. 2e.
Protein Identification
Ettan MALDI-ToF Pro MS spectral peaklists were submit-
ted to NCBI non-redundant database using ProFound™.
The Bruker Autoflex II MALDI ToF/ToF spectral peaklists
were submitted to the SwissProt database using Mascot.
Proteins with an expectation (probability) of <0.05 (indi-
cating a 5% statistical probability that the protein is a
random hit) was the criteria used for reporting results
retrieved with ProFound. Probability-based Mowse scores
greater than 54 were deemed significant (p<0.05) when
reporting search results retrieved with Mascot.
Discussion
The hypothesis to be tested in this study was that
immunodepletion of six high-abundance proteins from
plasma before 2D PAGE display would enhance the
detection and identification of disease-associated changes
in ovarian cancer plasma proteins. The data obtained
support this hypothesis in that removal of high-abundance
plasma proteins enriched residual proteins by an order of
magnitude and enabled the identification of differentially
expressed ovarian-cancer-associated proteins. The spot
density of 59 protein spots was greater than or equal to
twofold difference between displays of normal and ovarian
cancer samples (Student’s t test, p=0.01). Of these spots, 39
were confidently identified by peptide mass fingerprint
analysis. Proteins previously reported to be associated with
ovarian cancer were identified in plasma obtained from
women with high-grade tumors.
Table 1 Protein budget table of depletion process















2D clean-up (n=32) 52.4±2.4 4.84
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Fig. 1 Representative chro-
matogram of 4.6×50 mm
column depicting fractionation
of a human plasma sample into
low-abundant proteins and high-
abundant proteins. Arrows
indicate representative peaks
Fig. 2 2-D gel images of
MARS-treated plasma from
both the control and the cancer
samples separated on pH 4–7
strips and then resolved on 10%
gels. Protein load was 40 μg for
depleted plasma and 25 μg for
both neat and HAP. a Repre-
sentative protein profile from a
neat plasma sample. b Repre-
sentative protein profile from a
depleted control sample. Pro-
teins that are down-regulated are
depicted in yellow. c Represen-
tative protein profile from a
depleted cancer sample. Proteins
that are up-regulated are
depicted in red. d Representa-
tive protein profile from a de-
pleted plasma sample depicting
the HAP fraction only.
e Representative protein profile
from a depleted benign ovarian
neoplasm sample. Proteins that
are down-regulated are depicted
in yellow; proteins that are up-
regulated are depicted in red
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The data set that relates to benign ovarian neoplasm
demonstrated that with the exception of three proteins
exhibiting greater than or equal to twofold difference in
spot density (Student’s t test, p=0.01), the protein display
profiles are identical to the control group. None of the three
proteins identified represent any of the 59 proteins that
were found to be statistically different between the control
and cancer groups. These data further support and validate
the utility of the observed differential expression of proteins
we identified in the late-stage disease group.
As immunodepletion only reduced total plasma protein
content by 82%, it is more probable that differentially
expressed proteins identified represent high-abundance host
response proteins rather than from the tumor tissue. Indeed,
most of the proteins identified may be classified as proteins
affected by or intrinsic to the acute phase and/or inflam-
matory response. While this does not negate the potential
utility of such candidate proteins in multi-marker, multiplex
assays for ovarian cancer, it may impact on disease
specificity of such tests.
Of the ovarian-cancer-associated proteins identified,
afamin and vitamin D-binding protein are members of the
albuminoid gene superfamily and were both found to be
under expressed in OC. These findings are supported by
previous studies where afamin had been shown to be a
specific binding protein for vitamin E known to be essential
in protecting against oxidative damage and disease [12].
Further supporting these findings, Wu et al. showed that the
levels of afamin in hepatocellular carcinoma are signifi-
cantly reduced when compared to normal hepatocytes [13],
and a study from Cancer Research UK Clinical Centre also
confirmed that patients with ovarian cancer have decreased
levels of afamin and stated that, when used in conjunction
with CA125, it may have the potential as a clinical marker
of ovarian cancer [14].
Previously, Huang et al. investigated serum obtained
from patients with breast cancer and control subjects
utilizing 2D PAGE and MS and reported that hemoglobin
was up-regulated in cancer patients. Notably, haptoglobin
functions as a scavenger of hemoglobin and the increase in
serum haptoglobin levels observed in this study may be
consequential to the amplification in the level of the protein
[15]. The data obtained in this study support previous
observations that haptoglobin expression is increased in the
serum of grade 3 ovarian cancer patient when compared to
control serum [5]. It is important to note that the binding
Table 3 Protein characterization of proteins down-regulated















1 Afamin precursor 69.02 5.64 P43652 11 17 112 –
2 Afamin precursor 69.02 5.64 P43652 11 17 104 –
3 Afamin precursor 69.02 5.64 P43652 11 17 104 –
4 Afamin precursor 69.02 5.64 P43652 11 17 104 –
11 Fibrin beta 51.37 8.3 gi 223002 7 19.7 – 0.028
13 Vitamin D-binding protein
precursor
52.93 5.4 P02774 6 15 55 –
14 Vitamin D-binding protein
precursor
52.93 5.4 P02774 11 19 86 –
15 Apolipoprotein A_IV
precursor
45.37 5.28 P06727 21 50 243 –
16 Apolipoprotein A_IV
precursor
45.37 5.28 P06727 23 48 214 –
17 Chain D retinol binding
protein with transthyretin
12.98 5.30 gi 4558178 4 51.3 – 0.001
18 Transthyretin precursor 15.88 5.70 P02766 6 41 100 –
19 Apolipoprotein A_I precursor 30.76 5.56 P02647 19 53 188 –
20 Apolipoprotein A_I precursor 30.76 5.56 P02647 15 51 131 –
Table 2 Matching summary from PDQuest analysis of normal (n=16) and cancer (n=16) depleted plasma
Plasma sample Spot number
mean±SD
Spots matched (to master)
within replicate group






Normal (n=16) 349±26 300±30 172 NA NA
Grade 3 (n=16) 357±24 302±22 166 20 39
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capacity of the MARS column for haptoglobin is inade-
quate, and incomplete depletion is observed in our 2D
PAGE protein profiles of cancer patient plasma (Fig. 2c).
Zhang et al. [3] clearly demonstrated that the levels of
Apolipoprotein A–I and transthyretin are both down-regulated
in patients with ovarian cancer, and inter-alpha trypsin
inhibitor heavy chain H4 was up-regulated. Moore et al.
[16] was able to replicate these findings, and interestingly, in
our study, the expression of chain D retinol-binding protein
with transthyretin was also shown to be down-regulated.
Roberts et al. [17] reported that decreased levels of retinol
binding protein have been shown to be associated with an
increased rate of malignant transformation of the ovarian
epithelium and expression may be lost as early as stage 1 and
at high frequency. These findings may be critical in early
stage diagnosis.
Ceruloplasmin is an important copper–protein in serum
and is essential for iron transport across the cell membrane.
Recent studies have reported that ceruloplasmin may be
involved in cardiovascular disease [18] and pathological
brain conditions including inflammatory and neurodegener-
ative diseases, implicating the pro-inflammatory cytokine
interleukin-1beta(IL-1β) [19]. Interestingly, a concurrent
study in our laboratory (data not published) demonstrates
Table 4 Protein characterization of proteins up-regulated
















1 Ceruoplasmin precursor 122.1 5.44 P00450 16 18 118 –
2 Complement C3 precursor 187.1 6.02 P01024 12 10 67 –
3 Complement C3 precursor 187.1 6.02 P01024 8 7 56 –
4 Complement factor B
preproprotein
85.48 6.67 P00751 10 11 70 –
5 Inter-alpha-trypsin inhibitor
heavy chain H4 precursor
103.3 6.51 Q14624 12 19 82 –
6 Inter-alpha-trypsin inhibitor
heavy chain H4 precursor
103.3 6.51 Q14624 12 19 87 –
7 Inter-alpha-trypsin inhibitor
heavy chain H4 precursor
103.3 6.51 Q14624 13 19 85 –
8 Inter-alpha-trypsin inhibitor
heavy chain H4 precursor
103.3 6.51 Q14624 9 15 79 –
9 Inter-alpha-trypsin inhibitor
heavy chain H4 precursor
103.3 6.51 Q14624 9 15 79 –
17 Unnamed protein product 60.29 6.10 gi 29565 4 9.1 – 0.009
18 Alpha-1-antichymotrypsin
precursor
47.62 5.33 P01011 9 27 77 –
19 Alpha-1-antichymotrypsin
precursor
47.62 5.33 P01011 9 31 95 –
20 Alpha-1-antichymotrypsin
precursor
47.62 5.33 P01011 9 31 104 –
21 Alpha-1-antichymotrypsin
precursor
47.62 5.33 P01011 9 28 84 –
22 Alpha-1-antitrypsin precursor 46.71 5.37 P01009 17 48 154 –
23 Alpha-2-macroglobulin
precursor
46.71 6.00 P01023 10 8 61 –
24 Alpha-2-macroglobulin
precursor
46.71 6.00 P01023 11 10 63 –
26 Fibrinogen gamma chain
precursor
51.48 5.37 P02679 8 23 67 –
27 Alpha-1-antitrypsin precursor 46.71 5.37 P01009 10 35 87 –
28 Alpha-1-antitrypsin precursor 46.71 5.37 P01009 14 42 139 –
33 Haptoglobin precursor 45.18 6.13 P00738 11 24 117
34 Haptoglobin precursor 45.18 6.13 P00738 11 24 107
35 Haptoglobin precursor 45.18 6.13 P00738 12 24 108
36 Haptoglobin precursor 45.18 6.13 P00738 13 24 108
37 Haptoglobin precursor 45.18 6.13 P00738 6 17 63
38 Haptoglobin precursor 45.18 6.13 P00738 10 24 96
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the up-regulation of several interleukins in the serum of
cancer patients compared to controls, suggesting that these
cytokines may also play a crucial role in the expression of
ceruloplasmin noted to be over expressed in our study.
Recent authors have also shown that IL-1α enhances the
bio-synthesis of complement C3 and factor B [20], both of
which are also up-regulated in our protein profiles of cancer
patients, again, implicating the possible role of interleukins
in the progression of the disease [20, 21].
The role of fibrinogen has been implicated in the
production of cancerous cells with increased metastatic
potential [22], and the over expression of fibrinogen gamma
was identified in the sera of patients with pancreatic cancer
and determined to be a potential tumor marker for the
disease [23]. These studies further support our observations
of an up-regulation of the protein in ovarian cancer.
A comparative study of unfractionated breast carcinoma
and control sera also revealed that the levels of alpha-1-
antichymotrypsin, an acute-phase protein, were significant-
ly higher in all breast carcinoma patients that also concur
with our findings [24].
Conclusion
Immunodepletion of plasma 2D PAGE profiling increases
the identification of plasma proteins affected by the
presence of high-grade ovarian cancer. As such, this
approach may be useful in identifying candidate biomarkers
for inclusion in multi-marker tests for ovarian cancer that
are of greater sensitivity and specificity than are currently
available. Immunodepletion provides only an order of
magnitude enrichment of residue proteins; thus, it is more
likely that high-abundance, host-response proteins will be
identified using this approach than tumor-specific proteins.
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